Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 19/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SCN1A | P35498 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mefenorex SCHEMBL122442 | 0.98 | SIGMAR1 (0.70) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| Mefenorex SCHEMBL161841 | 0.97 | SIGMAR1 (0.68) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL30384619 | 0.89 | SIGMAR1 (0.86) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL20689707 | 0.87 | SIGMAR1 (0.86) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL20689714 | 0.87 | SIGMAR1 (0.86) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL20689723 | 0.87 | SIGMAR1 (0.86) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL29059547 | 0.85 | SIGMAR1 (0.81) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL22043230 | 0.84 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL4821356 | 0.84 | SIGMAR1 (0.79) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL4821348 | 0.84 | SIGMAR1 (0.79) | SIGMAR1ADRB2ADRB1HTR1AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2701 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20240075043-A1 | IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS FOR WEIGHT LOSS | Red Mountain Med Spa, LLC (US) | 2024-03-07 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20220362160-A1 | ABUSE RESISTANT CAPSULE | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-11-17 | — | — | US | claimed |
| US-11464747-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-10-11 | — | — | US | claimed |
| CN-114886889-A | Application of alantolactone or derivatives thereof in preparation of medicines, health products or foods for preventing or treating obesity | 清华大学 | 2022-08-12 | — | — | CN | claimed |
| CN-110585165-B | Abuse resistant capsules | R·P·谢勒技术有限公司 | 2022-08-12 | — | — | CN | claimed |
| US-20220249505-A1 | APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF | RED MOUNTAIN HOLDINGS, LLC (US) | 2022-08-11 | — | — | US | claimed |
| CN-114832019-A | Application of akkermansia muciniphila in preparation of pharmaceutical composition for preventing and treating obesity, composition and application thereof | 广州知易生物科技有限公司 | 2022-08-02 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0977572-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047513-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |
| US-5466466-A | Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substrates II | LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG (DE) | 1995-11-14 | — | — | US | claimed |
| EP-0384266-B1 | Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents | LOHMANN THERAPIE SYST LTS (DE) | 1994-07-20 | — | — | EP | claimed |
| US-5215751-A | THERAPEUTIC SYSTEM FOR THE RETARDED AND CONTROLLED TRANSDERMAL OR TRANSMUCOUS ADMINISTRATION OF ACTIVE SUBSTANCES (I) | LTS LOHMANN THERAPIE SYSTEME GMBH & CO. (DE) | 1993-06-01 | — | — | US | claimed |
| EP-0384267-B1 | THERAPEUTIC SYSTEM FOR THE SUSTAINED AND CONTROLLED TRANSDERMAL OR TRANSMUCOSAL DELIVERY OF ACTIVE AGENTS | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1993-05-26 | — | — | EP | claimed |
| EP-0384267-A2 | Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1990-08-29 | — | — | EP | claimed |
| EP-0384266-A2 | Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1990-08-29 | — | — | EP | claimed |